文献速递消化系统肿瘤

血浆ctDNA RAS突变分析用于转移性结直肠癌患者的诊断与治疗监测

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究评估了OncoBEAM™ RAS CRC检测血浆RAS突变状态与组织的一致性,并前瞻性监测纵向血浆样本中RAS突变。115例mCRC患者血浆与组织RAS总体一致率为93%,不一致主要由肿瘤空间和时间异质性解释。纵向监测显示RAS ctDNA可反映化疗/抗血管生成治疗反应,并检测抗EGFR治疗中RAS突变出现。

要点

  • 血浆与组织RAS检测总体一致率为93%(115例mCRC患者)。
  • 转移部位(腹膜、肺)、黏液性组织学及采血前治疗史可降低ctDNA中RAS检出。
  • 纵向RAS ctDNA监测可早期预测化疗/抗血管生成治疗反应并检测抗EGFR治疗中RAS突变出现。

核心结论

  • 血浆与组织RAS突变评估的高总体一致率支持基于血液的OncoBEAM™检测作为mCRC患者常规临床实践中RAS基因分型的可行替代方案。
  • 研究描述了优化RAS ctDNA检测的实用临床病理学规范。
  • OncoBEAM™可用于监测接受全身治疗患者的RAS以检测耐药并评估特定治疗的疗效。

研究设计与样本

  • 回顾性评估mCRC患者血浆与组织RAS突变状态的一致性,采用OncoBEAM™ RAS CRC检测。
  • 对选定患者的纵向血浆样本进行RAS突变前瞻性监测。
  • 共分析115例mCRC患者的组织和血浆样本。

主要发现

  • 115例mCRC患者血浆与组织RAS分析总体一致率为93%。
  • 血浆/组织RAS不一致主要由肿瘤空间和时间异质性解释。
  • 转移部位(腹膜、肺)、肿瘤组织学(黏液性)及采血前接受治疗对ctDNA中RAS检出有负面影响。
  • 基线RAS突变型患者接受化疗/抗血管生成治疗时,纵向RAS ctDNA分析反映治疗反应,为反应的早期预测指标。
  • RAS野生型患者中,纵向RAS ctDNA监测显示OncoBEAM有助于检测抗EGFR治疗期间出现的RAS突变。

临床怎么用

  • 作者认为血浆与组织RAS突变评估的高总体一致率支持基于血液的OncoBEAM™检测作为mCRC患者常规临床实践中RAS基因分型的可行替代方案。
  • 作者描述了优化RAS ctDNA检测的实用临床病理学规范。
  • 作者认为OncoBEAM™可用于监测接受全身治疗患者的RAS以检测耐药并评估特定治疗的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RAS assessment is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however, genotyping of circulating tumor (ct)DNA offers clear advantages as a minimally invasive method that represents tumor heterogeneity. Our study aims to evaluate the use of ctDNA as an alternative for determining baseline RAS status and subsequent monitoring of RAS mutations during therapy as a component of routine clinical practice. PATIENTS AND METHODS: RAS mutational status in plasma was evaluated in mCRC patients by OncoBEAM™ RAS CRC assay. Concordance of results in plasma and tissue was retrospectively evaluated. RAS mutations were also prospectively monitored in longitudinal plasma samples from selected patients. RESULTS: Analysis of RAS in tissue and plasma samples from 115 mCRC patients showed a 93% overall agreement. Plasma/tissue RAS discrepancies were mainly explained by spatial and temporal tumor heterogeneity. Analysis of clinico-pathological features showed that the site of metastasis (i.e. peritoneal, lung), the histology of the tumor (i.e. mucinous) and administration of treatment previous to blood collection negatively impacted the detection of RAS in ctDNA. In patients with baseline mutant RAS tumors treated with chemotherapy/antiangiogenic, longitudinal analysis of RAS ctDNA mirrored response to treatment, being an early predictor of response. In patients RAS wt, longitudinal monitoring of RAS ctDNA revealed that OncoBEAM was useful to detect emergence of RAS mutations during anti-EGFR treatment. CONCLUSION: The high overall agreement in RAS mutational assessment between plasma and tissue supports blood-based testing with OncoBEAM™ as a viable alternative for genotyping RAS of mCRC patients in routine clinical practice. Our study describes practical clinico-pathological specifications to optimize RAS ctDNA determination. Moreover, OncoBEAM™ is useful to monitor RAS in patients undergoing systemic therapy to detect resistance and evaluate the efficacy of particular treatments.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Vidal J, Muinelo L, Dalmases A, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017. PMID: 28419195. doi:10.1093/annonc/mdx125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。